Which has stronger valuation and earnings, SBTX or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is SBTX or AVTE more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Aerovate Therapeutics N/A -90.19% -77.47%

Which has higher valuation & earnings, SBTX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is SBTX or ELYM more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Eliem Therapeutics N/A -47.03% -45.97%

Which has stronger valuation & earnings, SBTX or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is SBTX or NLTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts prefer LWAC or SBTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, LWAC or SBTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is LWAC or SBTX more profitable?

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Do analysts rate CNTN or SBTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, CNTN or SBTX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is CNTN or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Silverback Therapeutics N/A -29.62% -28.20%

Silverback Therapeutics (SBTX) Competitors

$8.56 +0.62 (+7.81%)

As of 07/2/2026

Compare

SBTX vs. AVTE, ELYM, NLTX, LWAC, and CNTN

Should you buy Silverback Therapeutics stock or one of its competitors? MarketBeat compares Silverback Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silverback Therapeutics include Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), LightWave Acquisition (LWAC), and Hillstream Biopharma (CNTN).

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Aerovate Therapeutics	Neutral

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Summary

Silverback Therapeutics beats Aerovate Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to Eliem Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the broader market.

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Eliem Therapeutics	Neutral

Summary

Silverback Therapeutics beats Eliem Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Neoleukin Therapeutics	Neutral

Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Silverback Therapeutics beats Neoleukin Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to LightWave Acquisition?

LightWave Acquisition (NASDAQ:LWAC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
LightWave Acquisition	Neutral
Silverback Therapeutics	Neutral

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

LightWave Acquisition beats Silverback Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Silverback Therapeutics compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Hillstream Biopharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Hillstream Biopharma's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Hillstream Biopharma	Neutral
Silverback Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics' return on equity of -29.62% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

Hillstream Biopharma beats Silverback Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$308.66M	$955.37M	$7.00B	$12.42B
Dividend Yield	N/A	4.84%	2.67%	6.52%
P/E Ratio	-3.54	1.60	27.36	24.48
Price / Sales	N/A	114.19	536.36	94.85
Price / Cash	N/A	22.05	29.65	49.23
Price / Book	1.16	8.26	10.81	6.41
Net Income	-$89.48M	-$3.96M	$3.56B	$335.81M
7 Day Performance	N/A	-1.51%	2.19%	1.92%
1 Month Performance	N/A	2.66%	7.15%	5.22%
1 Year Performance	-48.18%	47.78%	35.43%	24.96%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$8.56 +7.8%	N/A	-48.2%	$308.66M	N/A	N/A	83	Gap Up High Trading Volume
AVTE Aerovate Therapeutics	N/A	$21.81 -1.8%	N/A	+93.1%	$632.16M	N/A	N/A	20	High Trading Volume
ELYM Eliem Therapeutics	N/A	$13.29 +1.9%	N/A	+907.8%	$395.40M	N/A	N/A	9	Gap Up High Trading Volume
NLTX Neoleukin Therapeutics	N/A	$33.88 +7.7%	N/A	+75.9%	$318.40M	N/A	N/A	90	High Trading Volume
LWAC LightWave Acquisition	N/A	$10.24 -0.2%	N/A	N/A	$307.99M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, ELYM, NLTX, LWAC, and CNTN

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Summary

How does Silverback Therapeutics compare to Hillstream Biopharma?

Summary

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, ELYM, NLTX, LWAC, and CNTN

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Which has stronger valuation and earnings, SBTX or AVTE?

Is SBTX or AVTE more profitable?

Does the media favor SBTX or AVTE?

Do institutionals and insiders believe in SBTX or AVTE?

Which has more volatility & risk, SBTX or AVTE?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Which has higher valuation & earnings, SBTX or ELYM?

Which has more risk and volatility, SBTX or ELYM?

Do institutionals and insiders hold more shares of SBTX or ELYM?

Is SBTX or ELYM more profitable?

Does the media prefer SBTX or ELYM?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Does the media prefer SBTX or NLTX?

Is SBTX or NLTX more profitable?

Which has stronger valuation & earnings, SBTX or NLTX?

Which has more risk and volatility, SBTX or NLTX?

Do institutionals and insiders have more ownership in SBTX or NLTX?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Which has higher earnings and valuation, LWAC or SBTX?

Does the media refer more to LWAC or SBTX?

Is LWAC or SBTX more profitable?

Do analysts prefer LWAC or SBTX?

Do institutionals and insiders believe in LWAC or SBTX?

Summary

How does Silverback Therapeutics compare to Hillstream Biopharma?

Which has more volatility and risk, CNTN or SBTX?

Do institutionals & insiders hold more shares of CNTN or SBTX?

Which has preferable earnings & valuation, CNTN or SBTX?

Does the media favor CNTN or SBTX?

Do analysts rate CNTN or SBTX?

Is CNTN or SBTX more profitable?

Summary

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools